Imaging of Brain Amyloid Plaques in the Aging Population

StatusEnrolling by Invitation
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv21
  2. Eligibility criteria expanded, about 5 wordsv20
  3. Primary and study completion dates: Jun 2024 to Jun 2027v19
  4. Study Status, Referencesv18
  5. Primary and study completion dates: Apr 2023 to Jun 2024v17
Show 15 earlier versionsHide 15 earlier versions
  1. Enrollment target: 5000 to 8000v16
  2. Enrollment target: 2500 to 5000v15
  3. Re-verified, no change to tracked fieldsv14
  4. Study Status, Referencesv13
  5. Primary and study completion dates: Apr 2018 to Apr 2023v12
  6. 4 versions Re-verified since Oct 12, 2015, no change to tracked fieldsv8-v11
  7. Interventions: F-18 FDG (Drug), Pittsburgh Compound B (C-11 PiB) (Drug) to F-18 FDG (Drug), Pittsburgh Compound B (C-11 PiB) (Drug), Tau (18-F-AV-1451) (Drug)
    • Eligibility criteria revised
    v7
  8. 3 versions Re-verified since May 31, 2012, no change to tracked fieldsv4-v6
  9. Enrollment target: 1000 to 2500
    • Secondary endpoints: details revised at 4 of 4 entries
    v3
  10. Trial status: Recruiting to Enrolling by Invitation
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mayo Clinic
1,026 trials monitored
See 131 trials at risk
Dementia
1,989 trials monitored
See 106 trials at risk
Alzheimer's Disease
1,261 trials monitored
See 69 trials at risk
This is a prospective, open label, non-therapeutic, diagnostic imaging study. The purpose of this study is to utilize Pittsburgh Compound B positron emission imaging (PiB PET) to ascertain the relationship between change in amyloid burden over time, and concurrent change in clinical status.
Trial Details
NCT Number NCT00950430
Lead Sponsor Mayo Clinic
Collaborators: National Institute on Aging (NIA)
Conditions
(from sponsor)		 Alzheimer's Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Vascular Dementia
Related terms Alzheimer Disease, Dementia, Dementia, Vascular, Frontotemporal Dementia, Lewy Body Disease
Enrollment 8,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov